ArticleCurrent microbiology2025
Bioactive Fraction of Streptomyces thinghirensis MSA1 Effectively Inhibits Biofilm Forming Clinically Significant AMR Pathogens.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- 2-Amino-3-Chlorobenzoic Acid fromPharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The escalating threat of antibiotic-resistant microorganisms necessitate the discovery of novel antibacterial agents. This study explores the potential of marine-associated actinomycetes, focusing on Streptomyces thinghirensis MSA1, isolated from the marine sponge Callyspongia diffusa in Palk Bay, India, for its notable antibacterial properties. To optimize the production of bioactive compounds of S. thinghirensis MSA1, we established optimal growth conditions (30 °C, pH 7, 2% salinity, 9-day incubation) and utilized ISP4 medium for enhanced secondary metabolite production. The extracted compound, MSA1, was analyzed through FTIR and GCMS, identifying 20 biologically active components. MSA1 demonstrated potent antibacterial activity against significant pathogens, including Escherichia coli, Klebsiella pneumoniae, Salmonella typhi, Pseudomonas aeruginosa, and MRSA, alongside remarkable antioxidant and anti-biofilm properties. These findings highlight the potential of MSA1 as a promising candidate for developing treatments against antibiotic-resistant infections. This study acknowledges the preliminary nature of the findings and the necessity for further in vivo and clinical trials to fully ascertain the therapeutic potential of MSA1. This research opens avenues for novel antibacterial agents in the fight against antibiotic resistance, underscoring the value of marine biodiversity in medical science.
Indexed as
Identifiers
40188414What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.